CENTRAL MEDICAL SERVICES SOCIETY
Ministry of Health & Family Welfare
(Autonomous Body under MoHFW, Govt. of India)
2nd Floor, Vishwa Yuvak Kendra, Pandit Uma Shankar Dikshit Road,
Chanakyapuri, New Delhi-110021 PHONE -:011-21410905/6, Fax -:011-21410849

Date: - 07.07.2023

Minutes of Pre-bid Meeting
For Procurement of TABLET RIFAPENTINE 300MG+ ISONIAZID 300MG for NTEP
CPP Tender ID: 2023_CMSS_759825_1, dated 29.06.2023
Pre-bid Meeting held on 04.07.2023 at 11:30 AM

1. Following officials were present during the Pre-bid meeting: -
   (i) Dr. Alok Mathur, Addl. DDG (NTEP)
   (ii) Mr. D Mohapatra, GM (Finance), CMSS
   (iii) Ms. Anjana, GM (Procurement), CMSS
   (iv) Mr. Lava Mishra, AGM (Procurement), CMSS
   (v) Ms. Akanksha Jain, AGM (QA), CMSS

2. Following representatives from prospective bidders were present during the Pre-bid meeting: -

Sr. No.	Name of Representative	Name of firm
1	Mr. Harish Joshi	M/s Macleod Pharma Ltd.
2	Mr. Pawan Chopra	M/s Bharat Parenterals
3	Mr. Atul Yadav	M/s Lupin Ltd.
4	Mr. Alok Kumar	M/s J Duncan Healthcare Pvt. Ltd.

3. Queries from following prospective firms were received via email: -

Sr. No.	Name of the bidders	
1	M/s. OXALIS LABS	M/s J Duncan Healthcare Pvt. Ltd.

4. Points raised by representatives of prospective bidders were discussed. After due consideration of the queries, the remarks are enclosed.

TABLE-A

Pre-bid queries raised by the prospective bidders & remarks by CMSS

Sr. No.	As per tender	Tender clause no.	Bidder's Representation	Bidder's Name	Response
1.	Tender timelines are as under: (d) Last date and time for bid submission: - 13/07/2023 at 3:00 PM	**Critical Date Sheet**	We request you to extend the deadline to submit the bid, the time given is less also we need time to get the documents from FDA, Bank and Chartered Accountant Documents which takes time to get and also as the tender format is changes, we need to work on all the documents again	M/s. OXALIS LABS	No changes.
			Kindly extend the Bid submission end date is 30/07/2023 at 3.00PM Reasons: - we had applied for approval of new product in form CT 23 to CDSCO, after approval from CDSCO, 7 working days required for obtaining the manufacturing License for domestic from SLA (State Licensing Authority). we are still waiting for approval from CDSCO.	M/s J Duncan Healthcare Pvt. Ltd.	
2.	**For SCH. I** TRANCHE I- 50% of the total quantity to be delivered within 90 days from the date of issue of LOA. TRANCHE II-25% of the total quantity to be delivered within 180-210 days from the date of issue of LOA. TRANCHE III-25 % of the total quantity to be delivered within 270-300 days from the date of issue of LOA.	Annexure I & IA - List of Product & Their Technical Specifications	And as on receipt of the LOA or PO, for the supply of drugs to CMSS, the supply period for Tranche I quantity as per the tender clause was 60 days from the date of issue of LOA which is likely not possible as because as below: - It takes minimum 30 to 60 days to complete with production dependency. After production, it takes a further 10 to 15 days to receive COA. After the products have been inspected by you, it takes additional 20-30 days to receive the inspection reports.	M/s. OXALIS LABS	**Amended as: -** TRANCHE I- 35% of the total quantity to be delivered within 90 days from the date of issue of LOA. TRANCHE II- 35% of the total quantity to be delivered within 180-210 days from the date of issue of LOA. TRANCHE III- 30% of the total quantity to be delivered within 270-300 days from the date of issue of LOA.

			Its takes at least 30 days for the goods to be delivered to all location, thus making the delivery possible in roughly 100 to 130 days. In light of the fact that it will actually be unable to get first tranche dispatched in 60 days, we hereby request you to kindly consider or give us a minimum of days rather than 120 days in order to seamless delivery without any LD Charges. Also, after goods readiness it takes time for Inspection Report for approx. 30 days thus increase the Lead time OR allow us to ship the goods parallel to inspection. OR if Tranche-1 (50%) is been converted in 2 lot i.e. 20:30 then we shall request you to consider 20% to be supplied in 90 days & balance 30% within 120 days. Kindly confirm.		
			Annexure I- Delivery Schedule For SCH. I TRANCHE I- 20% of the total quantity to be delivered within 60 days from the date of issue of LOA. TRANCHE II- 30% of the total quantity to be delivered within 61-120 days from the date of issue of LOA. TRANCHE III- 25% of the total quantity to be delivered within 180-210 days from the date of issue of LOA. TRANCHE IV- 25% of the total quantity to be delivered within 270-300 days from the date of issue of LOA. OR	M/s J Duncan Healthcare Pvt. Ltd.	

			TRANCHE I- 25% of the total quantity to be delivered within 90 days from the date of issue of LOA. TRANCHE II- 25% of the total quantity to be delivered within 91-180 days from the date of issue of LOA. TRANCHE III- 25 % of the total quantity to be delivered within 181-270 days from the date of issue of LOA. TRANCHE IV- 25 % of the total quantity to be delivered within 271-360 days from the date of issue of LOA. Reasons: - Huge Qty. and new drug in India time & supply of API.		
3.	3) Refer to Inspection Methodology (PDI/NON PDI) - Non-PDI (Inspection at Delivery Stages)	Annexure I & IA - List of Product & Their Technical Specifications	Refer to this clause we hereby request you to kindly reconfirm that we do not have to submit the CRC copy along with the post shipment documents as it is NON PDI. Please confirm	M/s. OXALIS LABS	CRC will not be applicable for this tender.
4.	Refer to Point pt # 18(18.2) — Delays in Suppliers Performance (page #33): - If the supply reaches the designated consignee places or CMSS Warehouse after scheduled delivery• date mentioned in LOA/P.O, liquidated damages will be levied @ 2.5% per week to be applied proportionately on per day basis up to a maximum of 10% of P.O. Cost, irrespective of the fact that whether the CMSS has suffered any damage/loss or not, on account of delay in effecting supply. If the last schedule delivery day happens to be a holiday the supply will be	**18.2**	Refer to this clause, we hereby request you to kindly remove this clause or to reduce the percentage of penalty per week	M/s. OXALIS LABS	No changes.
			Liquidated damages If the supply reaches the designated consignee places or CMSS Warehouse after scheduled delivery date mentioned in LOA/P.O, liquidated damages will be levied @ 0.5% per week to be applied proportionately on per day basis up to a maximum of 10% of un-supplied goods, irrespective of the fact that whether the CMSS has suffered any damage/ loss or not, on account of delay in effecting supply. If the last scheduled delivery	M/s J Duncan Healthcare Pvt. Ltd.	

	accepted on the next working day without any penalty.		day happens to be a holiday the supply will be accepted on the next working day without any penalty. **Reasons:- As per provision of GFR and Manual of Procurement and Guidelines of MoF (DoE).**		
5.	Miscellaneous		This is just to confirm from you that can we can use last tender format Tender No. CMSS/PROC/2023-24/NTEP/008 Dated 01.05.2023. Please confirm the same.	M/s. OXALIS LABS	All format and terms & conditions will be applicable according to tender ref no. CMSS/PROC/2023-24/NTEP/026.
6.	(i) Long Term (Real Time) Stability Data of the quoted product in specified packing for at least for 3 batches, to support shelf life. However, For the drugs recently introduced drugs in the county (introduced in the last two years), the requirement for Long Term (Real Time) Stability Data of the quoted product in specified packing for at least for 3 batches, to support shelf life shall be waived off. Point no (iii) shall be applicable. (II) Only for the drugs introduced in Indian Pharmacopoeia in the recent past (last 2yrs), Long Term (Real Time) Stability Data for previously approved Pharmacopoeia r.-- in-house Standards shall be accepted, as the case may be. (iii) Accelerated Stability data for a period of 6 months in specified packing for at least 3 batches and available Lung term (Real Time) stability data as available for the	**6 (n)**	Refer to this clause, we hereby request you to consider Long Term (Real Term) & Accelerated Term Stability Shelf Life to consider as Mandatory.	M/s. OXALIS LABS	No changes.

	quoted product shall be submitted. (iv) Certificate of Analysis of one batch of the quoted product should be submitted.				
7.	Tenderer shall be a manufacturer of the quoted product and having valid own manufacturing license in the indicate pharmacopeia (in technical specification at Annexure IA) and Certificate of Pharmaceutical Product (COPP) as recommended by WHO in any of the pharmacopeia IP/BP/USP. The manufacturing license & COPP should be valid on the date of tender opening packet 1. In case of failure to submit the same, the bid shall not be considered any further. The Tenderer should furnish the domestic Manufacturing License in Form of 25 / 28 issued from State Licensing Authority along with the approval of DCGI in Form of 46/ CT-23 as new drug approved by DCGI. For drugs that are not available in IP, other official Pharmacopeia (s) are applicable. If a drug is not available in any of the official pharmacopeias, 'In House' standards are applicable as per the Drugs and Cosmetics Act 1940 and the Rules therein. **Bidder is requested to submit an undertaking that the drug is not available in IP or any**	4 (c) & 6.2 (c)	Tenderer shall be a manufacturer of the quoted product and having valid own manufacturing license in the indicate pharmacopeia (in technical specification at Annexure IA) and Certificate of Pharmaceutical Product (COPP) as recommended by WHO in any of the pharmacopeia IP/BP/USP/**IHS (In House Standard).** The manufacturing license & COPP should be valid on the date of tender opening packet 1. In case of failure to submit the same, the bid shall not be considered any further. The Tenderer should furnish the **own** domestic Manufacturing License in Form of 25 / 28 issued from State Licensing Authority along with the approval of DCGI in Form of 46/ CT-23 as new drug approved by DCGI and **IPC (Indian Pharmacopeia Commission) Test report.** **Reasons- Drugs newly introduced in India and Programme Division NTEP procured first time in India. To establish the quality of the product above mentioned requirement are should be mandatory.** **The Tenderer should furnish the API Manufacturing License along with the approval of DCGI as new drug approved by DCGI and**	M/s J Duncan Healthcare Pvt. Ltd.	**Amended As: -** Tenderer shall be a manufacturer of the quoted product and having valid own manufacturing license in the indicate pharmacopeia (in technical specification at Annexure IA) and Certificate of Pharmaceutical Product (COPP) as recommended by WHO in any of the pharmacopeia IP/BP/USP/IHS (In House Standard). The manufacturing license & COPP should be valid on the date of tender opening packet 1. In case of failure to submit the same, the bid shall not be considered any further. The Tenderer should furnish the domestic Manufacturing License in Form of 25 / 28 issued from State Licensing Authority along with the approval of DCGI in Form of 46/ CT-23 as new drug approved by DCGI.

	other approved pharmacopeia.		**IPC (Indian Pharmacopeia Commission) Test report. To establish the quality source of API.** For drugs that are not available in IP, other official Pharmacopeia (s) are applicable. If a drug is not available in any of the official pharmacopeias, 'In House' standards are applicable as per the Drugs and Cosmetics Act 1940 and the Rules therein. Bidder is requested to submit an undertaking that the drug is not available in IP or any other approved pharmacopeia. **Loan License should not be eligible to bid.**		For drugs that are not available in IP, other official Pharmacopeia (s) are applicable. If a drug is not available in any of the official pharmacopeias, 'In House' standards are applicable as per the Drugs and Cosmetics Act 1940 and the Rules therein. **Bidder is requested to submit an undertaking that the drug is not available in IP or any other approved pharmacopeia.**
8.	Tenderer should quote at least for 50% of the tender quantity of each items quoted and the tenderer shall have an annual production capacity not less than one and half times the quantity quoted for each schedule.	**4 (h)**	Tenderer should quote at least **for 25% of** the tender quantity of each items quoted and the tenderer shall have an annual production capacity not less than one and half times the quantity quoted for each schedule. **Reasons: - API production is limited.**	M/s J Duncan Healthcare Pvt. Ltd.	No changes.
9.	Tenderer should have supplied 40% of the quoted quantity of same or similar items during the last two financial years. Bidder should submit Purchase order copies and certificate duly issued by statutory auditor of the company on his letter head by certifying the quantities manufactured and marketed in trade, export, open market, sold to government institutions, private bodies etc. and the marketed quantities	**4 (i) & 6.2 (e)**	Tenderer should have supplied 40% of the quoted quantity of same or similar items during the **last three financial years.** Bidder should submit Purchase order copies and certificate duly issued by statutory auditor of the company on his letter head by certifying the quantities manufactured and marketed in trade, export, open market, sold to government institutions, private bodies etc. and the marketed quantities are not	M/s J Duncan Healthcare Pvt. Ltd.	**Amended as: -** Tenderer should have supplied 40% of the quoted quantity of same or similar items during the last two financial years. Bidder should submit Purchase order copies and certificate duly issued by Statutory Auditor/Practising Chartered Accountant of the

	are not less than at least 40% of the quoted/ similar items. Similar Items here relate to the following: - Similar item means quoted/any TB Drug Supply/Sale/Service order under loan license arrangement shall not be considered.		less than at least 40% of the quoted/ similar items. Similar Items here relate to the following: - Similar item means quoted/any TB Drug Supply/Sale/Service order under loan license arrangement shall not be considered. **OR** Tenderer should have submit **any three Purchase order copies of any Govt. entities/ Autonomous body for any quantity of Anti TB Drugs during the last two financial years.** Bidder should submit Purchase order copies and certificate duly issued by statutory auditor of the company on his letter head by certifying the quantities manufactured and marketed to government institutions. **OR** Tenderer should have supplied 40% of the quoted quantity of same or similar items during the **last two financial years.** Bidder should submit Purchase order copies and certificate duly issued by statutory auditor of the company on his letter head by certifying the quantities manufactured and marketed in trade, export, open market, sold to government institutions, private bodies etc. and the marketed quantities are not less than at least 40% of the quoted/ similar items.		company on his letter head by certifying the quantities manufactured and marketed in trade, export, open market, sold to government institutions, private bodies etc. and the marketed quantities are not less than at least 40% of the quoted/ similar items. **Similar Items here relate to the following: -** Similar item means quoted/any TB Drug **Supply/Sale/Service order under loan license arrangement shall not be considered.**

			Similar Items here relate to the following: - **Similar item means any Tablet (we have Manufacturing Lic, CoPP, MMC- Manufacturing and Marketing standing certificate, Capacity Certificate which is issued by Licensing Authority).** **We had supplied various tablets in CMSS, BPPI, Punjab Health Corp., RMSCL, UPMSCL, MPPHSC, Maharashtra Govt,, OMSCL, BMSCL etc** Supply/Sale/Service order under loan license arrangement shall not be considered. **OR** Relaxation of Prior experience criteria for MSME and Startup entities as per Deptt. of Expenditure order no F.20/2/2014- PPD (pt.) dt. 20/09/2016. **Copy enclosed.** **Stipulated tender conditions also amended in CMSS previous tender also. (ARV Tender No-013 for 2023-24 for NACO, NACO HIV Kit Tender for 2022-23, NACO CD 4 Tender, DEC Tablet Tender for NVBDCP, First Line Anti TB Drugs etc.** **Stipulated tender conditions restrictive to participate the bidder and eliminate the wider participation.** **Stipulated tender conditions not required**		

			by Any other Govt. Procurement entities.		
10.	A valid Certificate of Pharmaceutical Product (COPP) as recommended by WHO in any pharmacopeia IP/BP/USP and a valid WHO-GMP.	**6 (i)**	Requirement of Certificate of Pharmaceutical Product (COPP) as recommended by WHO in any pharmacopeia IP/BP/USP **should be deleted.** A valid WHO-GMP should be submitted. **Reasons- Drugs recently introduced in India 2021.**	M/s J Duncan Healthcare Pvt. Ltd.	No changes.
11.	Duly notarized general power of Attorney (on non-judicial stamp paper of worth Rs. 50/-) in favour of authorized signatory in case of partnership firm (to be signed by all partners) / proprietorship firm or board resolution in case of a company to sign the bid and bind the bidder. The signature of authorized signatory should be duly attested. In case of proprietorship on its letter head of firm declares himself as proprietor with specimen signature.	**6 (d)**	Duly notarized general power of Attorney (on non-judicial stamp paper of **worth Rs. 50/- or more)** in favour of authorized signatory in case of partnership firm (to be signed by all partners) / proprietorship firm or board resolution in case of a company to sign the bid and bind the bidder. The signature of authorized signatory should be duly attested. In case of proprietorship on its letter head of firm declares himself as proprietor with specimen signature.	M/s J Duncan Healthcare Pvt. Ltd.	Accepted.
12.	Annexure-VIII NOTARISED UNDERTAKING BY MSE COMPANIES (In 20- Rupees stamp paper)		Annexure-VIII NOTARISED UNDERTAKING BY MSE COMPANIES (In 20- Rupees or more rupees stamp paper)	M/s J Duncan Healthcare Pvt. Ltd.	Accepted.
13.	Annexure III-EMD EMD For Sch. I- As per Annexure III.	Annexure III-EMD	**Bid security declaration also allowed in compliance of GFR 2017 Rule no 170(iii).** In place of a Bid security, the Ministries/ Departments may require Bidders to sign a Bid securing declaration accepting that if they withdraw or modify their Bids during the period of validity, or if they are awarded the contract and they fail to sign the	M/s J Duncan Healthcare Pvt. Ltd.	No changes.

			contract, or to submit a performance security before the deadline defined in the request for bids document, they will be suspended for the period of time specified in the request for bids document from being eligible to submit Bids for contracts with the entity that invited the Bids. **Reasons: - Wider participation for small entities.**		
14.	Typo Error: Online short tender for procurement of Tablet Rifapentine 300 mg + Isoniazid 30 mg for NTEP		It should read as: Online short tender for procurement of Tablet Rifapentine 300 mg + Isoniazid 300 mg for NTEP. **Kindly clarify**	M/s Lupin Ltd.	Kindly read Tablet Rifapentine 300 mg + Isoniazid 300 mg in place of Tablet Rifapentine 300 mg + Isoniazid 30 mg where it is mentioned in the tender document.
15.	All the tenderers are required to supply the products with printed Text " NACO SUPPLIES - NOT FOR SALE" in red colour on the strips, blisters, vials, ampoules & bottles and also on the external packings.	14.7: Supply/Delivery Conditions	In the technical specifications (Annexure 1 A), it is mentioned as NTEP Central Government Supply NOT FOR SALE. Also, the logo of NTEP is mentioned. Kindly clarify if we should additionally include the printed text " NACO supplies - NOT For SALE in red colour on the strips, and also on the external packings	M/s Lupin Ltd.	**Amended as: -** All the tenderers are required to supply the products with printed Text " NTEP SUPPLIES - NOT FOR SALE" in red colour on the strips, blisters, vials, ampoules & bottles and also on the external packings.
16.	6.2 d Technical Bid-Packet 1: The signature of authorized signatory should be duly attested.		Kindly confirm if attestation by authorized company official is acceptable	M/s Lupin Ltd.	No changes.
17.	**Inspection Methodology (PDI/Non PDI): -** Non-PDI (Inspection at Delivery Stages)	**Annexure - I**			**Amended as: -** **Inspection Methodology (PDI/Non PDI): -** Tranche I: - PDI (Pre-delivery Inspection)

					Rest Tranche 2 & 3: - Non-PDI (Inspection at Delivery Stages)
18.	Manufacturing and Market Standing Certificate / Market Standing Certificate issued by the Licensing Authority as a manufacturer for each item quoted for the last 2 years i.e. 2020-21 & 2021-22 OR 2021-22 & 2022-23 for compliance of tender clause no. 4 (d).	**6.2 (f)**			**Amended as: -** Deleted.
19.	For all regulated products, the bidder should have at least two years i.e. 2020- 21and 2021-22 OR 2021-22 and 2022-23 of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCG (I) in less than two years ago. A permission from DCG (I) shall be required for all new regulated products to this effect. Only for the drugs introduced in Indian Pharmacopoeia in the recent past last 2yrs), Market standing certificate for previously approved Pharmacopoeia or Inhouse Standards (Export/ Domestic) shall be accepted, as the case may be. For the recently introduced drugs in the county (introduced in the last two years), the requirement for Market standing certificate shall be waived off.	**4 (d)**			**Amended as: -** Deleted.
20.	Annexure-IV should be signed by Statutory Auditor	**Annexure-IV**			**Amended as: -** Annexure-IV should be signed by Statutory Auditor/ Practicing Chartered Accountant
21.	Storage: Store protected from light and moisture at room temperature.	**Annexure-IA, Technical Specification B. Storage**			**Amended as: -** Storage: Store protected from light and moisture at room temperature. (25°C

		& Shelf-life			(77deg F); excursions permitted 15-30 ℃ (59-86 deg F)
22.		**Annexure-IA, Technical Specification A & K Packaging**			**Amended as: -** A strip consisting of individual blisters of the drug duly identified should be packed in an Aluminium- PVC blister pack/Alu-Alu strip pack.

Note: - Above changes will be part of the tender document.

(Anjana)
GM (Procurement)